Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol
| Autor: | Britt Kveiborg, Atheline Major-Petersen, Buris Christiansen, Christian Torp-Pedersen |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Adrenergic beta-Antagonists Carbazoles Hypoglycemia Propanolamines Insulin resistance Internal medicine Diabetes mellitus medicine Diabetes Mellitus Animals Humans Pharmacology (medical) Carvedilol Metoprolol business.industry General Medicine medicine.disease Bosentan Endocrinology Glucose Heart failure Metabolic control analysis Cardiology Insulin Resistance Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | American journal of cardiovascular drugs : drugs, devices, and other interventions. 6(4) |
| ISSN: | 1175-3277 |
| Popis: | Although beta-adrenoceptor antagonists (beta-blockers) have effects on metabolism via their mechanism as blockers of adrenergic stimulation, most interest in the metabolic effects of beta-blockers is caused by their effect on glucose metabolism. Strict metabolic control and management of cardiovascular risk factors in patients with diabetes mellitus has proven to be of great importance in the improvement of prognosis. Beta-blockers are necessary tools for the treatment of heart failure and hypertension. The use of beta-blockers in patients with diabetes mellitus has been controversial because of fear of deterioration of metabolic control of glucose and lipids and blunting of the symptoms of hypoglycemia. Currently, it appears that there is a beneficial metabolic effect with the third-generation beta-blocker carvedilol. Comparisons have been made between the second-generation beta-blocker metoprolol and carvedilol, with a clear advantage for carvedilol in terms of metabolic control. In the GEMINI (Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives) trial, a decrease of 9.1% (p = 0.004) in insulin resistance, compared with baseline values, was seen in patients treated with carvedilol, whereas no significant difference was seen in the group of patients treated with metoprolol. Additionally, an increase in glycosylated hemoglobin of 0.15% from baseline was seen in the metoprolol group (p < 0.001) compared with no significant change in the carvedilol group. These findings indicate that, as carvedilol exerts favorable effects on glucose metabolism compared with metoprolol, patients with diabetes mellitus could benefit from treatment with carvedilol rather than metoprolol. The mechanisms behind these findings are not yet fully understood. Several mechanisms have been suggested, and special interest has been paid to the investigation of the potential beneficial role of the beta2- and alpha1-adrenoceptor-blocking effects of carvedilol, along with its known antioxidant properties. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink